fda import alert green list glp-1 semaglutide tirzepatide 2025 66-80: and Peptide Bulk API Now Detained at the Border FDA introduces "Green List" for

Dihexa has never undergone rigorous human clinical trials establishing dosing parameters

Its injectable route adds logistical complexity in longer clinical studies but is standard practice in preclinical rodent work

Data from epidemiological evidence, such as the EPIC-Oxford Study or the Adventist cohorts, show quite broadly how a healthy lifestyle, including PA and exercise, along with plant-predominant (including vegan) diets, can contribute to long-term sustainable health (100, 385, 386)

The results of GLP-1 agonists are truly life-changing, but we also know that lifestyle and nutrition support are necessary companions to achieving long-term success

For medical providers, navigating the payer landscape is not optional

10.1089/ars.2020.8141 Pubmed Abstract CrossRef Google Scholar View reference in article 68